You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased.
Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.
Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.
News items for the in vitro diagnostics industry for the week of April 27, 2020.
BioMérieux's BioFire received clearance for its Blood Culture Identification 2 Panel for the identification of nucleic acids associated with bacteria and yeast.
The company said the revenue increase is driven primarily by growth in the life science segment due to high demand for SARS-CoV-2 molecular products.
The analyzer and assay use immunofluorescent technology to detect H. pylori antigens in human stool and helps eliminate subjectivity.
The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.
The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.
